Hotelbuchung
Hotel Registration
Grußwort
Welcome address
Beteiligte Gesellschaften
Societies involved
DOG Information
DOG Information
Eröffnung des Kongresses
Opening Ceremony
Preise
Awards
Ablauf der Tagung 2003
General overview of congress
Lageplan der Räumlichkeiten
Map of Congress Center
Wissenschaftliche Themen
Scientific topics
Symposien
Symposia
Wissenschaftliches Programm
Scientific program
Posterpräsentationen
Poster Presentation
Kurse
Courses
Begleitende Veranstaltungen
Accompanying program
Arbeitssitzungen
Working sessions
Rahmenprogramm
Social program
Allgemeine Informationen
General Information
Autorenindex
Index of Authors
Industrieaussteller
Commercial exhibitors
Sponsoren
Sponsors
Impressum
DOG Homepage
Abstract
Abstract
Selective Anti-TNF-alpha Therapy of Chronic Therapy in Resistent Anterior Segment Inflammation
El-Shabrawi Y., Hermann J.
Dep. of Ophthalmology, Karl-Franzen-University Graz/A
Purpose: Intraocular inflammatory diseases are a leading cause of visual impairment and blindness. Of those patients that develop recurrent or chronic anterior uveitis 23% will have a drop of vision below 20/50. The percentage of legally blind patients is 11%. Thus the treatment of these patients with chronic or recurrent uveitis still presents a quite a challenge, and additional treatment modalities are needed. Thus we tested the efficacy of selective anti-TNFa therapy in chronic inflammatory diseases of the anterior segment of the eye, non-responsive to or not tolerating standard antiinflammatory treatment consisting of a combined immunomodulatory and corticosteroid therapy.
Method: Nine patients suffering from a uveitis associated with a systemic disease were included in this study. Eight patients were suffering from a rheumatic disease, of these five from a spondylarthropathy, two of JIA (one Stills disease, one ANA positive oligoarthritis patient) and one patient had a necrotizing sclerouveitis in association with Wegener granulomatosis. One additional patient with a uveitis associated with tubulointerstitial nephritis (TINU syndrome) was also included. DMARD therapy was initiated at least 3 months prior to infliximab therapy. It consisted of methotrexate (MTX) in 7 patients, of which two received a combination of MTX and mycofenolate-mofetil. One patient received cylophosphamide, another p